Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
The purpose of this study is to purpose of this study is to assess if regorafenib is active enough, in terms of 6-month progression-free rate, to warrant further comparative studies in patients with RAS-mutant advanced colorectal cancer who have progressed after first-line oxaliplatin-based chemotherapy plus bevacizumab.
Critère d'inclusion
- Advanced colorectal cancer